Figure 2. Adoptive transfer of TRAIL⁺ T cells does not cause lethal GVHD.

(A, B, D, and E) Lethally irradiated CBF1 recipients were reconstituted with 5 × 10⁶ cells per recipient of WT B6 TCD BM. Designated groups were treated with (A and D) 0.5 × 10⁶ cells per recipient or (B and E) 1 × 10⁶ cells per recipient of B6-derived GFP⁺ or TRAIL⁺ T cells. Survival was monitored and clinical GVHD scores were recorded weekly in a blinded fashion. (C and F) Lethally irradiated B6 recipients were reconstituted with 5 × 10⁶ cells per recipient of WT B10.BR TCD BM. Designated groups were treated with 1 × 10⁶ cells per recipient of B10.BR GFP⁺ or TRAIL⁺ T cells. Survival was monitored (A–C) and clinical GVHD scores were recorded weekly (D–F) in a blinded fashion. *P < 0.05; **P < 0.01; ***P < 0.001.